6Mathet VL, Feld M, Espfnola L, et al. Hepatitis B virus S gene mutants in a patient with chronic active hepatitis with circulating AntiHBs antibodies. J Med Virol, 2003, 69: 18-26.
7Mesenas S J, Chow WC, Zhao Y, et al. Wild-type and ‘a' epitope variants in chronic hepatitis B virus carriers positive for hepatitis B surface antigen and antibody. J Gastroenterol Hepatol, 2002, 17: 148-152.
8Lada O, Benhamou Y, Poynard T, et al. Coexistence of hepatitis B surface antigen (HBsAg) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of ‘a’ determinant variants. J Virol, 2006, 80: 2968-2975.
9Zheng X, Weinberger KM, Gehrke R, et al. Mutant hepatitis B virus surface antigens (HBsAg) are immunogenic but may have a changed specificity. Virology, 2004, 329: 454-464.
10Bartholomeusz A, Schaefer S. Hepatitis B virus genotypes: comparison of genotyping methods. Rev Med Virol, 2004, 14: 3-16.
3Sanchez MJ,Buti M,Homs M,et al. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemo- therapy containing rituximab [ J ]. Hepatol, 2009,51 ( 6 ) : 1091.
4Gouas D,Shi H,Hainaut P,et al. The aflatoxin - induced TP53 muta- tion at eodon 249 ( R249S ) : biomarker of exposure, early detection and target for therapy[J]. Cancer Lett,2009,286( 1 ) :29.
5Tsai WL, C hung RT. Viral h epatocarcinogenesis [ J]. Oncogene,2010, 29(16) :2309.
